Archives of Clinical Infectious Diseases

Published by: Kowsar

New Advances in Treatment of Chronic Hepatitis B Infection

Masoud Mardani 1 , *
Author Information
1 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Clinical Infectious Diseases: October 5, 2012, 7 (4); 107-8
  • Published Online: October 5, 2012
  • Article Type: Editorial
  • Received: July 29, 2012
  • Revised: August 3, 2012
  • Accepted: August 16, 2012
  • DOI: 10.5812/archcid.15385

To Cite: Mardani M. New Advances in Treatment of Chronic Hepatitis B Infection, Arch Clin Infect Dis. 2012 ; 7(4):107-8. doi: 10.5812/archcid.15385.

Copyright © 2012, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnotes
References
  • 1. Brooks J, Gelson W, Rushbrook SM. Therapeutic advances in the management of chronic hepatitis B infection. Ther Adv Chronic Dis. 2013; 4(4): 157-66[DOI][PubMed]
  • 2. del Canho R, Grosheide PM, Schalm SW, de Vries RR, Heijtink RA. Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J Hepatol. 1994; 20(4): 483-6[PubMed]
  • 3. Chen M, Sallberg M, Hughes J, Jones J, Guidotti LG, Chisari FV, et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol. 2005; 79(5): 3016-27[DOI][PubMed]
  • 4. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352(26): 2682-95[DOI][PubMed]
  • 5. Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology. 2000; 32(5): 1145-53[DOI][PubMed]
  • 6. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007; 357(25): 2576-88[DOI][PubMed]
  • 7. Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol. 2012; 57(3): 508-14[DOI][PubMed]
  • 8. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology. 2011; 53(3): 763-73[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments